|
|
|
|
||
Re: If this company's future is so bright...For whatever it is worth, this is a copy of something I posted on the Yahoo board in response to the poster named Doc, when we were discussing and trading some study papers. I didn't get any reply, so I don't know how off-base I might be - so anyone here with more knowledge, please feel free to chime in and correct anything I've posted: ----------------- From the Wikipedia article on AV2-73: "ANAVEX2-73 acts as a muscarinic receptor and a moderate sigma1 receptor agonist." "Muscarinic receptors are involved in the formation of both short term and long term memories.[1] Experiments in mice have found that M1 and M3 receptor agonists inhibit the formation of amyloid-beta and target GSK-3B...Therefore, M1 receptor activation appears to decreases tau hyperphosphorylation and amyloid-beta accumulation." In other words, amyloid-beta formation, which is a precursor to the formation of amyloid plaques (common in AD) is suppressed. "Sigma1 activation appears to be only involved in long-term memory processes...ANAVEX2-73 inhibits mitochondrial respiratory dysfunction and therefore prevents against oxidative stress and apoptosis." The Sigma-1 receptor protein appears to have an effect on the endoplasmic reticulum, and by activating it seems to reduce what is called endoplasmic reticulum stress - which appears to cause problems with protein folding. It is this problem that seems to be involved in the formation of amyloid plaques. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3709793/ |
return to message board, top of board |